Key Presentation at ESMO Asia Congress
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a pioneering oncology company dedicated to overcoming therapeutic resistance, has exciting news to share. They are set to showcase critical findings from their Phase 1b trial of enozertinib (ORIC-114) at the upcoming ESMO Asia Congress. This congress is an essential gathering of healthcare professionals, taking place on December 5-7, 2025.
The Focus of the Presentation
The presentation will emphasize how enozertinib significantly impacts patients with HER2 exon 20 mutant non-small cell lung cancer (NSCLC) who have undergone prior treatments. These results highlight the potential of tailored therapies in managing complex cancer cases.
Details of the Poster Presentation
The poster titled "Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor in Patients with HER2 Exon 20 Mutant NSCLC: Randomized Dose Optimization," will be an integral part of the conference. With a presentation number of 981P, it will fall under the poster display session.
Timing and Session Information
Scheduled for Friday, December 5, 2025, from 5:15 p.m. to 6:15 p.m. SGT, the poster presentation aims to attract attention from both oncologists and researchers interested in the latest advancements in cancer therapeutics.
Conference Call and Webcast Insights
Moreover, in conjunction with the ESMO Asia Congress, ORIC will conduct a conference call and a live webcast on December 6, 2025. This event is a valuable opportunity for investors and interested parties to engage in discussions and learn more about the trial outcomes and future directions for enozertinib.
How to Participate
To join the call and gain unique insights into ORIC’s innovative approaches, participants are encouraged to pre-register online. This will provide the necessary access codes to facilitate involvement in the Q&A segment following the presentation. A recording of the event will also be available on the company's website for later viewing, ensuring that interested individuals do not miss these critical discussions.
About ORIC Pharmaceuticals
Founded with a mission to enhance the lives of patients battling cancers, ORIC Pharmaceuticals is committed to developing innovative therapies that target the underlying mechanisms of resistance. Their lead candidate, enozertinib (ORIC-114), is a unique brain-penetrant inhibitor, designed to address specific mutations in EGFR and HER2 that often lead to treatment failures in various cancers.
Continued Commitment to Cancer Research
ORIC also develops ORIC-944, which targets the polycomb repressive complex 2 in prostate cancer. This dedication underscores their broader vision of delivering meaningful advancements in oncology treatments, aimed at improving patient outcomes across a range of cancers.
Connecting with ORIC Pharmaceuticals
For those interested in more information about the company’s groundbreaking work, ORIC encourages visits to their website where comprehensive details on their pipeline and ongoing projects can be found. ORIC maintains robust engagement through social media platforms, providing updates on their latest research and developments.
Frequently Asked Questions
What is enozertinib being studied for?
Enozertinib is currently being studied for its effects on HER2 exon 20 mutant non-small cell lung cancer (NSCLC), particularly in patients with prior treatment.
When will the poster presentation take place?
The poster presentation will take place on December 5, 2025, at the ESMO Asia Congress.
What are the key highlights of the conference call?
The conference call will focus on providing insights and details about ORIC's recent clinical trial results, particularly concerning enozertinib.
Who can participate in the conference call?
Individuals interested in the developments and outcomes of ORIC Pharmaceuticals’ trials can pre-register to participate in the conference call.
How can I learn more about ORIC Pharmaceuticals?
For further information, you can visit ORIC Pharmaceuticals' website and follow them on social media for the latest updates.
